Enhanced Expression of Autoantigens During SARS-CoV-2 Viral Infection

Narjes Saheb Sharif-Askari1, Fatemeh Saheb Sharif-Askari1, Samrein B. M. Ahmed1,2, Suad Hannawi3, Rifat Hamoudi1,2,4, Qutayba Hamid1,2,5 and Rabih Halwani1,2,6*

1 Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates, 2 Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates, 3 Department of Rheumatology, Ministry of Health and Prevention, Dubai, United Arab Emirates, 4 Division of Surgery and Interventional Science, University College London, London, United Kingdom, 5 Meakins-Christie Laboratories, Research Institute of the McGill University Healthy Center, McGill University, Montreal, QC, Canada, 6 Prince Abdullah Ben Khaled Celiac Disease Research Chair, Department of Pediatrics, Faculty of Medicine, King Saud University, Riyadh, Saudi Arabia

Immune homeostasis is disturbed during severe viral infections, which can lead to loss of tolerance to self-peptides and result in short- or long-term autoimmunity. Using publicly available transcriptomic datasets, we conducted an in-silico analyses to evaluate the expression levels of 52 autoantigens, known to be associated with 24 autoimmune diseases, during SAR-CoV-2 infection. Seven autoantigens (MPO, PRTN3, PADI4, IFIH1, TRIM21, PTPRN2, and TSHR) were upregulated in whole blood samples. MPO and TSHR were overexpressed in both lung autopsies and whole blood tissue and were associated with more severe COVID-19. Neutrophil activation derived autoantigens (MPO, PRTN3, and PADI4) were prominently increased in blood of both SARS-CoV-1 and SARS-CoV-2 viral infections, while TSHR and PTPRN2 autoantigens were specifically increased in SARS-CoV-2. Using single-cell dataset from peripheral blood mononuclear cells (PBMCs), we observed an upregulation of MPO, PRTN3, and PADI4 autoantigens within the low-density neutrophil subset. To validate our in-silico analysis, we measured plasma protein levels of two autoantigens, MPO and PRTN3, in severe and asymptomatic COVID-19. The protein levels of these two autoantigens were significantly upregulated in more severe COVID-19 infections. In conclusion, the immunopathology and severity of COVID-19 could result in transient autoimmune activation. Longitudinal follow-up studies of confirmed cases of COVID-19 could determine the enduring effects of viral infection including development of autoimmune disease.

Keywords: autoantigen, bioinformatics, SARS-CoV-2, COVID-19, autoimmune disease, neutrophil, respiratory viral infection, lung autopsies
INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19), appeared first in Wuhan, China, in December 2019 and has since rapidly spread globally (1, 2). COVID-19 severity level ranged from asymptomatic infection to life-threatening disease (3–6). Severe COVID-19 disease has been associated with innate immune dysregulation, early immunosuppression, lymphopenia, and cytokine storm (7–10).

Multiple factors are involved in the development of autoimmunity, including genetics, age, and environment (11). Between the environmental triggers, viral infections, particularly those resulting in low interferon production, as it is the case with SARS-CoV-2 infection, have long been associated with induction of autoimmunity (11). Similar to many severe viral infections, SARS-CoV-2 could trigger the autoimmune reaction through multiple mechanism including molecular mimicry, epitope spreading, bystander activation, and persistence of latent virus (12–15). Aforementioned mechanisms could be understood through examination of homology between various antigens of SARS-CoV-2 and self-antigens (16). Development of cross-reactive epitopes are then dependent on viral strain as well as host genetic susceptibility, including human leucocyte antigen (HLA) polymorphism.

Alternatively, viral induced inflammation and dysregulation of innate and adaptive immune system, could both directly and indirectly lead to loss of tolerance to self-peptides and result in short- or long-term autoimmunity (17, 18). Emerging reports are associating COVID-19 infection with worsening, relapse or de novo induction of several autoimmune diseases including systemic lupus erythematosus (19–21), Guillain-Barré syndrome (22, 23), vasculitis (24, 25), and multiple sclerosis (26). Further, high prevalence of antinuclear antibodies (ANA) and lupus anticoagulant were reported in severe hospitalized SARS-CoV-2 infection, which could hint at induction of autoimmunity (27).

Although the concept of autoimmunity had been explored in previous viral infection (28), its relevance to COVID-19 respiratory infection deserves more attention; especially that immune derangement during SARS-CoV-2 infection could potentially trigger relapse and induction of many new cases. Therefore, the aim of current study was to utilize publicly available transcriptomic COVID-19 data to evaluate autoimmune activation during COVID-19 infection through measuring the gene expression levels of 52 autoantigens, known to be associated with 24 different autoimmune diseases.

MATERIAL AND METHODS

For the purpose of this study, we used a list of 52 autoantigens established by Burbelo et al. (29) for diagnosis of 24 different autoimmune disease including Hashimoto’s thyroiditis, ANCA-associated vasculitis, rheumatoid arthritis (RA), and Systemic lupus erythematosus (SLE) (Table 1). The expression of these autoantigens in the lungs and whole blood of COVID-19 patients...
was then determined in-silico using publicly available datasets. We validated autoantigen with mRNA expression equal or more than 1.5 LogFC change in leucocyte isolated from COVID-19. These datasets were publicly available at the National Center for Biotechnology Information Gene Expression Omnibus (NCBI GEO, http://www.ncbi.nlm.nih.gov/geo) and the European Bioinformatics Institute (EMBL-EBI, https://www.ebi.ac.uk). Moreover, single cell transcriptomic datasets of sorted neutrophils were used. In addition, the expression of autoantigens following COVID-19 infection was compared to that following infection with three respiratory viruses: SARS-CoV-1, IAV, and RSV.

RNA-sequencing platforms were used for COVID-19 studies, while microarray platforms were used for older datasets of SARS-CoV-1, IAV, and RSV (Table 2). For the COVID-19 lung autopsies dataset (PRJNA646224) (32), the authors have extracted RNA from Formalin fixed paraffin embedded (FFPE) tissues from 9 COVID-19 fatal cases, and 10 SARS-CoV-2-uninfected individuals who undertook biopsy as part of routine

| Autoantigen | Full name | Autoimmune disease | Location |
|-------------|-----------|---------------------|----------|
| AQP4 | aquaporin 4 | Neuromyelitis optica | 18q11.2 |
| GAD2 | glutamate decarboxylase 2 | Stiff-person syndrome, T1D | 10p12.1 |
| INS | insulin | Type I diabetes (T1D) | 11p15.5 |
| PTMPN | protein tyrosine phosphatase receptor type N | Type I diabetes | 2q35 |
| PTMPN2 | protein tyrosine phosphatase receptor type N2 | Type I diabetes | 7q36.3 |
| SLC30A8 | solute carrier family 30 member 8 | Graves’ disease (GD) | 1q24-q31 |
| TSHR | thyroid stimulating hormone receptor | Hashimoto’s thyroiditis, GD | 2p25.3 |
| TG | thyroglobulin | Hashimoto’s thyroiditis, GD | 8q24.22 |
| CHRNA1 | cholinergic receptor nicotinic alpha 1 subunit | Myasthenia gravis | 2q31.1 |
| MUSK | muscle associated receptor tyrosine kinase | Myasthenia gravis | 9q31.3 |
| LRP4 | LDL receptor related protein 4 | Myasthenia gravis | 11p12.2 |
| COL4A3 | collagen type IV alpha 3 chain | Goodpasture disease | 2q36.3 |
| PLA2R1 | phospholipase A2 receptor 1 | Membranous nephropathy | 2q23-q24 |
| THSD7A | thrombospondin type 1 domain containing 7A | Membranous nephropathy | 7p21.3 |
| CYP21A2 | cytochrome P450 family 21 subfamily A member 2 | Addison’s disease | 6p21.33 |
| ATP4A | ATPase H+/K+ transporting subunit alpha | Autimmune gastritis | 19q13.12 |
| ATP4B | ATPase H+/K+ transporting subunit beta | Autimmune gastritis | 13p34 |
| CBLF (GIF) | cobalamin binding intrinsic factor | Autimmune gastritis | 11q12.1 |
| SEPSECS | Sep (O-phosphoserine) tRNA : Sec (selenocysteine) tRNA synthase | Autimmune hepatitis | 4p15.2 |
| CYP2D6 | cytochrome P450 family 2 subfamily D member 6 | Autimmune hepatitis | 22q13.2 |
| FTCD | formimidoyltransferase cycloheximidase | Autimmune hepatitis | 21q22.3 |
| DSG1 | desmoglein 1 | Pemphigus | 18q12.1 |
| DSG3 | desmoglein 3 | Pemphigus | 18q12.1 |
| TGMS | transglutaminase 3 | Dermatitis herpetiformis | 20p13 |
| CSF2 | colony stimulating factor 2 | Pulmonary alveolar proteinosis | 5q31.1 |
| PRRN3 (PR3) | proteinase 3 | ANCA-associated vasculitis | 19p13.3 |
| MPO | myeloperoxidase | ANCA-associated vasculitis | 17q22 |
| IFNγ | interferon gamma | Disseminated non-tuberculosis | 12q15 |
| PADI4 | peptidyl arginine deiminase 4 | Rheumatoid arthritis | 1p36.13 |
| TRIM21 | tripartite motif containing 21 | Sjögren’s syndrome, SLE | 11p15.4 |
| RO60 (TROVE2) | Ro60, Y RNA binding protein | Sjögren’s syndrome, SLE | 1q32.1 |
| SSB | small RNA binding exornuclease protection factor La | Sjögren’s syndrome, SLE | 2q31.1 |
| SNRPA | small nuclear ribonucleoprotein polypeptide A | Systemic lupus erythematosus (SLE) | 19q13.3 |
| SNRP70 | small nuclear ribonucleoprotein U1 subunit 70 | Systemic lupus erythematosus | 19q13.33 |
| SNRPD3 | small nuclear ribonucleoprotein D3 polypeptide | Systemic lupus erythematosus | 22q11.23 |
| HARS1 | histidyl-tRNA synthetase | Myositis | 5q13.3 |
| TARS1 | theonyr-tRNA synthetase 1 | Myositis | 5q13.3 |
| EXOSC9 | exosome component 9 | Myositis | 4q27 |
| EXOSC10 | exosome component 10 | Myositis | 1p36.22 |
| CHD4 | chromodomain helicase DNA binding protein 4 | Myositis | 12p13.31 |
| CHD3 | chromodomain helicase DNA binding protein 3 | Myositis | 17p13.1 |
| IFIH1 | interferon induced with helicase C domain 1 | Myositis | 2q24.2 |
| MORC3 | MORC family CW-type zinc finger 3 | Myositis | 21q22.12 |
| MRPS4 | signal recognition particle 54 | Myositis | 14q13.2 |
| TRIM50 | tripartite motif containing 33 | Myositis | 1p13.2 |
| HMGCR | 3-hydroxy-3-methylglutaryl-CoA reductase | Myositis | 5q13.3 |
| FBL | fibrillin | Scleroderma | 19q13.2 |
| TOP1 | DNA topoisomerase I | Scleroderma | 20q12 |
| POLR3A | RNA polymerase III subunit A | Scleroderma | 10q22.3 |
| DLAT | dihydrolipoamide S-acetyltransferase | Primary biliary cirrhosis | 11q23.1 |
| TGM2 | transglutaminase 2 | Celiac disease | 20q11.23 |
clinical care for lung cancer. For this lung autopsy datasets, we used processed sequencing data provided by Wu Meng et al. (32). The authors used DESeq2 to identify differentially expressed genes between the cases and controls. Benjamini-Horchberg correction was used for multiple testing (37).

For COVID-19 whole blood transcriptomic dataset, we used processed sequencing data deposited under project number EGAS00001004503 (33). In this study, Aschbenbrenner et al. extracted the RNA from whole blood of 39 COVID-19 patients and 10 healthy controls and analyzed it using NovaSeq 6000 (33). The authors used DESeq2 to identify differentially expressed genes between the cases and controls. Independent hypothesis weighting was used for multiple testing correction (33). Transcriptomic datasets of leucocytes isolated from 10 controls, 51 moderate COVID-19, 49 severe COVID-19 (12 non-critical and 37 critical) were used to validate the results of autoantigens with mRNA expression levels of equal or greater than 1.5 log fold change (GSE157103) (34). For leukocytes study, we processed the raw data using the Bioconductor package limma-voom (38), and presented the results as logCPM. Log-transformed normalized intensities were also used in Linear Models for MicroArray data (LIMMA) analyses to identify differentially expressed genes between diseased and control groups. We used the default Benjamini-Horchberg correction for multiple testing. Raw data from different studies were never mixed or combined. For each study, the LogFC was obtained separately by analyzing data of diseased and controls. Statistical analyses were performed using R software (v 3.0.2) and Prism (v8; GraphPad Software). For all analyses, p-values <0.05 were considered significant.

For the single cell dataset, transcriptomic datasets of sorted neutrophils were used. Wilk, AJ, et al. (36) performed single sequencing on PBMC from seven COVID-19 patients, and six healthy controls. The details of sample isolation, sequencing, and data processing are available at NCBI GEO, and the study protocols (36). Briefly, PBMCs (GSE150728) were isolated from blood via standard Ficoll-Paque density gradient centrifugation. Authors performed the single-cell RNA-seq library preparation using a Nextera XT DNA library preparation kit (Illumina FC-131-1096) with 1 ng of pooled library and dual-index primers. Sequencing was performed on a NovaSeq S2 instrument (Illumina; Chan Zuckerberg Biohub) (36). Differentially expressed genes (DEGs) were calculated by comparing gene expression of individual COVID-19 samples with gene expression of all healthy controls using Seurat’s implementation of the Wilcoxon rank-sum test. Only DEGs with a two-sided p value <0.05 adjusted for multiple comparisons by Bonferroni’s correction were selected. The investigators clustered neutrophils in to two clusters, low-density neutrophils and canonical neutrophils. The novel cell population of low-density neutrophils was significantly increased only in patients with ARDS.

**Gene Ontology**

Gene ontology enrichments analyses was performed using DisGeNET (41) and Gene Ontology biology process databases. Metascape.org (42) was used to identify the enrichment in DisGeNET (41). Terms with a p-value <0.01, a minimum count

### Table 2: Gene expression datasets used in this study.

| Groups                    | GEO accession | Platform   | Sample                                    | Condition 1                  | Condition 2                  |
|---------------------------|---------------|------------|-------------------------------------------|-----------------------------|-----------------------------|
| **Microarray Data**       |               |            |                                           |                             |                             |
| GSE1778 (30)              | GPL201        | PBMCs      | Controls (n = 4)                           | SARS-CoV-1 (n = 10)         |
| GSE17156 (31)             | GPL571        | Whole blood| Controls (n = 17)                          | Influenza H3N2 (n = 17)     |
| GSE17156 (31)             | GPL571        | Whole blood| Controls (n = 20)                          | Respiratory syncytial virus (n = 20) |
| **RNA-seq Data**          |               |            |                                           |                             |                             |
| PRUNA646224 (32)          | GPL21697      | Lung autopsies | Controls (n = 10)                        | Lung autopsies (n = 9)      |
| EGAS00001004503 (33)      | GPL24676      | Whole blood| Controls (n = 10)                          | COVID-19 (n = 39, 19 mild and 20 severe) |
| GSE157103 (34)            | GPL24676      | Leukocytes from whole blood | Controls (n = 10)            | moderate COVID-19 (n = 51), severe COVID-19 (n = 49, 12 non-critical and 37 critical) |
| Panousis et al. (35)      | GPL11154      | Whole blood| Controls (n = 58)                          | Active systemic lupus erythematosus (n = 79) |
| **Single-cell RNA-seq Data** |               |            |                                           |                             |                             |
| GSE150728 (36)            | GPL24676      | Peripheral blood mononuclear cells  | Healthy (n = 6)              | Severe COVID-19 (n = 7)     |

SARS-CoV, Severe acute respiratory syndrome coronavirus.
of 3, and an enrichment factor >1.5 were collected and grouped into clusters based on their membership similarities. The top few enriched clusters (one term per cluster) were presented. Gene Ontology biology process database was accessed through Enrichr open source, available as a gene set enrichment analysis web server (43, 44). GO biological processes were ranked according to combined score. This score was computed in Enrichr by taking the log of the p-value from the Fisher exact test and multiplying that by the z score of the deviation from the expected rank (43, 44).

ELISA

The plasma level of MPO and PRTN3 (PR3) for seven non-infected controls, eight severe, and eight asymptomatic COVID-19 patients was determined using commercially available human ELISA kit (MPO, Cat # ab119605 and PR3, Cat # ab226902, Abcam, Cambridge, MA, USA). The plasma used in our study was obtained from COVID-19 patients recruited from Rashid Hospital. Plasma was isolated from blood via standard Ficoll-Paque density gradient centrifugation (Sigma, Histopaque-10771). Assays were preformed strictly following the manufacturer’s instructions. Each sample was assayed in duplicate, and values were expressed as the mean of 2 measures per sample. One-way analysis of variance (ANOVA) and post hoc Tukey multiple comparison analyses were applied.

RESULTS

MPO and TSHR autoantigens Are Associated With More Severe COVID-19 in Lung Autopsy and Whole Blood

Using publicly available transcriptomic datasets, we have determined the expression levels of 52 autoantigens, known to be associated with 24 different autoimmune diseases. The list of these genes and their associated autoimmune disease is presented in Table 1. The datasets used in this study are presented in Table 2. Expression levels of autoantigens were determined in lung autopsies and whole blood (Figure 1). For lung, RNA-sequencing data was obtained from 9 deceased COVID-19 patients and 10 negative controls (PRJNA646224) (Figure 1A). For whole blood, RNA-sequencing data was extracted from 10 controls, 19 mild COVID-19, 20 severe COVID-19 (Figures 1B, C). MPO and TSHR were the only two autoantigens overexpressed in lung autopsies and were shared between the lung and blood of severe COVID-19 patients. In whole blood study, seven autoantigens were upregulated in blood of severe COVID-19 patients (MPO, PRTN3, PADI4, IFIH1, TRIM21, PTPRN2, and TSHR) (Figure 1B), while four autoantigens (MPO, PRTN3, IFIH1, and PADI4) were increased in blood of mild patients (Figure 1C). The upregulation of MPO and PRTN3 was significantly higher in...
severe versus mild COVID-19 (MPO, 3.4 ± 0.3 vs 1.9±0.3 log fold change [LogFC]; p-value = 0.004, and PRTN3 (2.9 ± 0.5 vs 1.6 ± 0.5 LogFC; p-value = 0.01 as presented in Figure 1C). We also looked at the levels of the selected seven autoantigens during active systemic lupus erythematosus (SLE) autoimmune disease using whole blood transcriptomic data deposited by Panousis et al. (35). Of the seven autoantigens, six markers were also upregulated during active SLE, however, MPO (3.4 ± 0.3 vs 0.9 ± 0.2 LogFC; p-value <0.0001), PRTN3 (2.9 ± 0.5 vs 1.2 ± 0.4 LogFC; p-value = 0.007), and PADI4 (1.8 ± 0.3 vs 0.4 ± 0.2 LogFC; p-value = 0.04) levels were significantly higher in severe COVID-19 blood (Figure 1D).

We next screened the expression of these seven genes in a second COVID-19 dataset of leukocyte transcriptome (GSE157103) (Figure 2). Out of the seven genes, four autoantigens (MPO, PRTN3, PADI4, and TSHR) were upregulated in leukocytes of COVID-19 patients, while three autoantigens (MPO, PRTN3, and PADI4) were significantly higher in severe versus moderate COVID-19. We have presented the results of leukocyte transcriptomic in Figure 2.

We next used gene ontology databases to determine general diseases associated with these seven genes (Figure 3A). DisGeNET database was pooled using publicly available metascape.org tool showing that beside autoimmune disease, these genes were associated with other inflammatory and fibrotic conditions affecting different organs including lung (Bronchiectasis; MPO, PRTN3, and TRIM21) and kidney (Glomerulonephritis; MPO, PRTN3, TRIM21, and PADI4). In addition, the GO biological process database revealed the association of these seven genes with interferon alpha signaling, neutrophil activation, and regulation of cytokine production (Figure 3B).

### Upregulation of Autoantigens in Low-Density Neutrophils During COVID-19 Infection

After establishing an overall upregulation of autoantigens in lung autopsies and whole blood COVID-19 patients, we next determined whether the observed increase in autoantigens is reflected on the main inflammatory cells regulating COVID-19 severity. We extracted the neutrophil and lymphocyte counts from PRJNA646224 study and compared the neutrophil to lymphocyte ratio between 16 mild and 15 severe COVID-19 patients. As presented in Figure 4A, severe COVID-19 had significant higher neutrophil to lymphocyte ratio. Next, a single cell dataset of immune cells isolated from peripheral blood mononuclear cells (PBMCs)
**FIGURE 3** | Gene ontology enrichments identified in the DisGeNET and Gene Ontology biology process databases. (A) Summary of enrichment of DisGeNet category of Metascape. Terms with a p-value <0.01, a minimum count of 3, and an enrichment factor >1.5 (the enrichment factor is the ratio between the observed counts and the counts expected by chance) are collected and grouped into clusters based on their membership similarities. The top few enriched clusters (one term per cluster) were presented. (B) Top 10 categories of the GO biological processes. GO analysis associated with the top seven differentially expressed autoantigens was performed using Enrichr. Bar lines represent cumulative score for the 10 top-ranked categories of GO biological processes. Combined score is computed by taking the log of the p-value from the Fisher exact test and multiplying that by the z score of the deviation from the expected rank.

**FIGURE 4** | Neutrophil to lymphocyte ratio and gene expression isolated from severe COVID-19 patients. (A) Neutrophil to lymphocyte ratio from whole blood of 16 mild and 15 severe COVID-19 patients were compared (PRJNA646224). This ratio was significantly higher in severe COVID-19. (B) Single-cell RNA sequencing was performed on PBMCs from six severe COVID-19 patients and seven healthy controls (GSE150728). Differential expression of MPO, PRTN3, and PADI4 within the low-density neutrophils cluster. (C) Increased counts of low-density neutrophil and canonical neutrophil during severe COVID-19 infection. The count value represents the absolute cell number within the PBMCs. Unpaired student t-test was used to compare between the independent groups. *p < 0.05, **p < 0.01, ***p < 0.001.
(GSE150728) of COVID-19 severe patients were used (36). Between the different immune cells three autoantigens, MPO, PRTN3, and PADI4, were significantly enriched within the low-density neutrophil subset (Figure 4B). Moreover, the counts of low-density neutrophil and canonical neutrophil were increased during severe COVID-19 infection (Figure 4C). To validate our in-silico analysis, we next measured plasma protein levels of two autoantigens of MPO and PRTN3 in severe and asymptomatic COVID-19. The protein levels were estimated using human ELISA assays. The results revealed an increase of MPO (mean 36,787 ± 1,961 vs mean 29,007 ± 1,860 pg/ml; p-value = 0.038) and PRTN3 (mean 151.5 ± 38 vs mean 14.77 ± 1.4 ng/ml; p-value = 0.001) in severe compared to asymptomatic COVID-19 infection (Figure 5). Level of these proteins were not different in asymptomatic and non-infected controls (Figure 5).

Prominent Autoantigens Upregulation in Coronavirus Infections Relative to Other Viral Infections

We next compared the profile of autoantigen upregulation observed during SARS-CoV-2 to that detected during other respiratory viral infection. To do that, we used transcriptomic microarrays and RNA-sequencing data from blood of SARS-CoV-1, influenza A virus (IAV), and respiratory syncytial virus (RSV) infected patients at the peak of disease. For each condition, differential expression and LogFC were obtained by comparing the normalized gene expression of the infected group versus healthy donors (Figure 6A). None of autoantigens were upregulated more than one LogFC in IAV and RSV, while five autoantigens in SARS-CoV-1 and seven autoantigens in SARS-CoV-2 were upregulated more than one LogFC (Figure 6A). MPO, PRTN3 (PR3), and PADI4 were the top shared autoantigens appearing in both coronavirus respiratory infections, with an increase in expression of more than 1.5 LogFC. We then intersected the differentially expressed genes in all four respiratory infections to obtain the shared signatures (Figure 6B). Interestingly, TSHR and PTPRN2 autoantigens were specifically increased in SARS-CoV-2 (Figure 6B). TSHR was also overexpressed in COVID-19 lung autopsies. Two genes (IFIH1 and TRIM21) were upregulated in three viral infections; however, their expression was higher in SARS-CoV-2 compared to IAV, and RSV (Figure 6B).

DISCUSSION

Herein we report the common autoantigens during COVID-19 viral infection. Fifty-two autoantigens, which are linked with 24 different autoimmune diseases, were tested (29). Seven autoantigens were found to be elevated in COVID-19. The level

![Elevated plasma MPO and PRTN3 levels in severe COVID-19 patients. An increase in the plasma levels of MPO and PRTN3 in severe compared to asymptomatic COVID-19 patients. The protein levels were estimated using human ELISA assays (n = non-infected controls, n = 8 asymptomatic COVID-19, and severe n = 8 COVID-19). *p < 0.05, **p < 0.01, ***p < 0.001.](image-url)
of three autoantigens, MPO, PRTN3, and PADI4, were higher in the blood of severe compared to mild COVID-19.

Autoimmune disease could be triggered by genetic and environmental factors; viral infections had been known as a major environmental cause of transient autoimmunity that could potentially lead to relapse or induction of de novo autoimmune disorders (11). These autoimmune disorders emerge weeks post viral infection; hence sensitive serological tests are needed to determine the cause-effect relationship between SARS-CoV-2 infection and autoimmune disease diagnosis (45–47).

Interestingly, MPO and TSHR were increased in both lung autopsies and whole blood of severe COVID-19 patients. Comparison of COVID-19 blood transcriptomic with IAV and RSV revealed that MPO, PRTN3, and PADI4 were selectively upregulated in coronavirus infections, SARS-CoV-1 and SARS-CoV-2, while TSHR and PTPRN2 autoantigens were distinctive to SARS-CoV-2 infection. These two genes (TSHR and PTPRN2) did not increase in the mild COVID-19 and hence they were associated with more severe infection.

Following the results obtained through gene ontology enrichment analyses, single cell transcriptomics of PBMCs revealed the significant increase in MPO, PRTN3, and PADI4 mRNA levels within low-density neutrophils. In addition, analyses of cell counts provided by Wilk et al. study showed significant increase in both low-density and canonical neutrophils during severe COVID-19 infection compared to controls (Figure 4C) (36).

The top seven autoantigens upregulated in the blood of severe COVID-19 patients, were associated with a wide range of vascular and inflammatory autoimmune disorders (Figure 3A). Vasculitis, a shared condition between fatal COVID-19 and vascular autoimmune diseases such as Anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, is featured by elevation of MPO and PRTN3 levels (25, 48). Wilk et al. single cell data identified a distinct group of low-density neutrophil; these immune cells were only detected in severe COVID-19 complicated with acute respiratory distress syndrome (ARDS) (36). These cells had a significantly high level of MPO, PRTN3, and PADI4 indicating that they could be a major source of the observed increase in blood level of these autoantigens during severe COVID-19. Following SARS-CoV-2 infection, neutrophil-derived extracellular traps (NETs) formation by neutrophils, NETosis, may therefore lead to burst of autoantigens including PADI4, MPO, and PRTN3 in the context of immunostimulatory molecules.

Confirming previous findings (49, 50), increased MPO level reflected COVID-19 severity. Neutrophil activation leading to net formation or NETosis is observed in both viral infections and autoimmune diseases (47, 51, 52). NETosis could then be considered as a common pathological modulator of viral infection and autoimmune disease (47, 52, 53). NETosis autoantigens, MPO, PRTN3, and PADI4, were markedly increased in SARS-CoV-1 and SARS-CoV-2 but they did not appear in IAV and RSV. Supporting our findings, a recent
investigation by FP Veras et al. showed viable SARS-CoV-2 ability to directly induce the release of NETs by healthy neutrophils (54). While, in another study, influenza A virus infection did not affect MPO release (55). MPO is a peroxidase enzyme responsible for intracellular catalytic reactions between hydrogen peroxidase and chlorides to form hypochlorous acid (56, 57). NETosis leads to extracellular burst of chromatic, histones, and neutrophil granules containing MPO, PRTN3, and PADI4. An exaggerated increase in the level of these antigens during COVID-19 infection could lead to breaking the autoimmune tolerance and the recognition of autoantigens by immune sentinel cells.

NETosis induces inflammation and DNA deployment that could trigger autoimmunity. While NET produced by neutrophils, their clearance is achieved by macrophages efferocytosis. During ARDS, neutrophil count and lifespan is significantly increased, and the ability of macrophages to engulf NETs and apoptotic cells is significantly decreased, prolonging the lung injury induced by neutrophil blast. Pharmacologic treatment could be used to enhance NETs clearance. Macrophage NETs efferocytosis could be restored by AMP-activated protein kinase (AMPK) activator such as Metformin or application of neutralizing antibody against HMGB1 (58). Therefore, such medications could be considered to reduce blood levels of these autoantigens, and hence lower chance of triggering autoimmunity.

TSHR is expressed by thyroid epithelial cells, and various extra-thyroidal tissue including the adipose, peripheral blood cells, and fibrocytes (59). Derived from monocytes, human fibrocytes express both thyroglobulin and thyrotropin receptor (60). They are increased during lung injury and have both the inflammatory characters of macrophages and the tissue remodeling features of fibroblasts (61). Chronic inflammatory conditions such as autoimmunity, cardiovascular disease, and asthma promote differentiation of immune cells to circulating fibrocytes and their accumulation at the site of injury (61, 62).

TSHR is targeted by autoantibodies during Graves’ disease (63). SARS-CoV-2 infection has been connected with the initiation and relapse phases of Grave disease (45, 46). Of note, this disease has emerged in some patients during COVID-19 recovery period. Patients diagnosed were negative for nasopharyngeal swab PCR test but were positive for both IgM and IgG SARS-CoV-2 antibodies. This suggests that the observed increase of autoantigens during SARS-CoV-2 infection may trigger autoimmunity. This could lead to initiation or relapse of autoimmune disorders as a long-term COVID-19 outcome. In fact, evidence of transient autoimmunity has been reported among long COVID-19 outcomes by several studies (64–66). Follow-up data from survivors of viral infections have shown appearance of autoimmune disorders within weeks to months after recovery (67). In addition, TSHR elevation was only detected in severe COVID-19, which could suggest higher chance for appearance of autoimmune disorders post severe COVID-19 infection.

The majority of COVID-19 patients are expected to show one or more residual symptoms months after recovering from the infection (68). In a post-acute COVID-19 follow-up study of 179 confirmed cases in Italy, fatigue and dyspnea persisted in around half of recovered individuals, while joint pain and chest pain lingered in 20–30% of recovered patients (68). Similarly, a 6-month follow-up study of 1,733 COVID-19 hospitalized patients from China reported lasting of fatigue and muscle weakness in more than half of patients, while patients who were more severely ill during their hospital stay had more persisting long-term symptoms (71).

Emerging case reports have shown that SARS-CoV-2 induces long-term immune-inflammatory abnormalities (66, 72). Schenker et al. reported a 65-year-old female patient with de novo reactive arthritis and cutaneous vasculitis 10 days after recovery of all COVID-19-related symptoms (72). In a more severe case, a 31-year female was presented with fatal multisystem inflammatory syndrome (MIS) 2 weeks post recovery from COVID-19 (65). This increase in incidence of autoimmunity was also reported among children, where SARS-CoV-2 epidemic was associated with a 30-fold increase in Kawasaki-like disease (71).

Long-COVID-19 persisting symptoms involve immune-mediated inflammatory disease and neurological abnormalities that could suggest possibility of triggering pre-existing or de novo autoimmune reactions weeks or month after COVID-19 recovery (37, 73). Previous studies have shown that autoantigen gene upregulation is often followed by an increase in the respective autoantibody level (29, 48, 74). Although the increase in autoantigen expression observed in this study could only trigger short lasting autoimmunity, follow-up longitudinal studies are needed to establish the long-term enduring effects of SARS-CoV-2 infection in developing autoimmune diseases.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/supplementary material.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Dubai Health Authority. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

RaH, QH, NSS-A, FSS-A, conceived and designed the experiments. NSS-A, FSS-A, RaH, RiH, SH and SA analyzed the data. All authors contributed to the article and approved the submitted version.

**FUNDING**

This research has been financially supported by Tissue Injury and Repair (TIR) group operational grant (Grant code: 150317); COVID-19 research grant (CoV19-0307) and (CoV19-0308),
Seed grant (Grant code: 2001090275); and by collaborative research grant (Grant code: 2001090278) to RH, University of Sharjah, UAE; and by a Sandooq Al Watan Applied Research & Development grant to RH (SWARD-S20-007); and by Al Jalia Foundation Seed Grant (AJF202019); and by Prince Abdullah Ben Khalid Celiac Disease Research Chair, under the Vice Deanship of Research Chairs, King Saud University, Riyadh, Kingdom of Saudi Arabia.

REFERENCES

1. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A New Coronavirus Associated With Human Respiratory Disease in China. Nature (2020) 579(7798):265–9. doi:10.1038/s41586-020-02088-3
2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus From Patients With Pneumonia in China. 2019. N Engl J Med (2020) 382(8):727–33. doi:10.1056/NEJMoa2001017
3. Chen H, Guo J, Wang C, Luo Y, Fu X, Zhang W, et al. Clinical Characteristics and Intrauterine Vertical Transmission Potential of COVID-19 Infection in Nine Pregnant Women: A Retrospective Review of Medical Records. Lancet (2020) 395(10226):497–506. doi:10.1016/S0140-6736(20)30360-3
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan, China. Lancet (2020) 395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
5. Rotte C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-ncov Infection From an Asymptomatic Contact in Germany. N Engl J Med (2020) 382(10):970–1. doi:10.1056/NEJMoa2001468
6. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med (2020) 382(10):929–36. doi:10.1056/NEJMoa2001191
7. Vardhana SA, Wolchok JD. The Many Faces of the anti-COVID Immune Response. J Exp Med (2020) 217(6):e20200678. doi:10.1084/jem.20200678
8. Blanco-Melo D, Nilsson-Payant BE, Liu W-C, Uhl S, Hoagland D, Moller R, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell (2020) 181(5):1036–45. doi:10.1016/j.cell.2020.04.026
9. Lee JS, Park S, Jeong HW, Ahn JY, Choi SJ, Lee H, et al. Immunophenotyping of COVID-19 and Influenza Highlights the Role of Type I Interferons in Development of Severe COVID-19. Sci Immunol (2020) 5(49):eaab1554. doi:10.1126/sciimmunol.aba1554
10. Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. Single-Cell Landscape of Bronchoalveolar Immune Cells in Patients With COVID-19. Nat Med (2020) 26(6):842–4. doi:10.1038/s41591-020-0901-9
11. Fujinami RS. Viruses and Autoimmune Disease—Two Sides of the Same Coin? Trends Microbiol (2001) 9(8):377–81. doi:10.1016/S0966-842X(01)02097-2
12. Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular Mimicry, Antiphospholipid Syndrome Related to COVID-19 Infection and Rheumatic Disease. Autoimmun Rev (2020) 19(7):102557–6. doi:10.1016/j.autrev.2020.102557
13. Reddy V, Desai A, Krishna SS, Vasanthapuram R. Molecular Mimicry Could be Associated With Both Transient Immunosuppression and an Inappropriate Form of Immune Reconstitution in Susceptible Individuals. Med Hypotheses (2020) 145:110345. doi:10.1016/j.mehy.2020.110345
14. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies Against Type I IFNs in Patients With Life-Threatening COVID-19. Science (2020) 370(6515). doi:10.1126/science.abb4585
15. Mantovani Cardoso E, Fiordaliso F, Tomelleri G, Mandala M, Pinto L, et al. Concomitant New Associated Vasculitis and Thrombotic Complications: From Pathological Findings to Multidisciplinary Discussion. Rheumatology (2020) 59(12):e147–50. doi:10.1093/rheumatology/keaa581
16. Alberti P, Serretta S, Pietti M, Karantouzis A, Piatti ML, Santoro P, et al. Guillain–Barré Syndrome Associated With SARS-CoV-2. N Engl J Med (2020) 382(26):2574–6. doi:10.1056/NEJMoa2009191
17. Zanin L, Saraceno G, Pancianni PP, Renisi G, Signorini L, Migliorati K, et al. SARS-CoV-2 Can Induce Brain and Spine Demyelinating Lesions. Acta Neuropathol (2020) 162(7):1491–4. doi:10.1007/s00401-020-02374-x
18. Gazzaruso C, Carlo Stella N, Mariani G, Nai C, Coppola A, Naldani D, et al. High Prevalence of Antinuclear Antibodies and Lupus Anticoagulant in Patients Hospitalized for SARS-CoV2 Pneumonia. Clin Rheumatol (2020) 39(7):2095–7. doi:10.1007/s10067-020-05180-7
19. Ercolini AM, Miller SD. The Role of Infections in Autoimmune Disease. Clin Exp Immunol (2019) 155(1):1–5. doi:10.1111/cei.13834
20. Barbolo PD, Iadarola MJ, Alevizos I, Sapos MB. Transcriptomic Segregation of Human Autoantigens Useful for the Diagnosis of Autoimmune Diseases. Mol Diagn Ther (2016) 20(5):415–27. doi:10.1007/s40291-016-0211-6
21. Reghunathan R, Jayapal M, Hsu LY, Chng HH, Tai D, Leung BP, et al. Expression Profile of Immune Response Genes in Patients With Severe Acute Respiratory Syndrome. BMC Immunol (2005) 6:2. doi:10.1186/1471-2415-6-2
22. Zaas AK, Chen M, Varkey T, Veldman T, Hero AO 3rd, Lucas J, et al. Gene Expression Signatures Diagnose Influenza and Other Symptomatic Respiratory Viral Infections in Humans. Cell Host Microbe (2009) 6(3):207–17. doi:10.1016/j.chom.2009.07.006
23. Wu M, Chen Y, Xia H, Wang C, Tan CY, Cai X, et al. Transcriptional and Proteomic Insights Into the Host Response in Fatal COVID-19 Cases. Proc Natl Acad Sci (2020) 117(45):28336. doi:10.1073/pnas.2018030117
24. Aschenbrenner AC, Moktaroudi M, Kramer B, Oestreich M, Antonakos N, Nuesch-Germano M, et al. Disease Severity-Specific Neutrophil Signatures in Blood Transcriptomes Stratify COVID-19 Patients. Genome Med (2021) 13(1):7. doi:10.1186/s13073-020-00823-5
25. Overmyer KA, Shishkova E, Miller IJ, Balnis J, Bernstein MN, Peters-Clarke M, et al. Combined Genetic and Transcriptome Analysis of Patients With SLE: Distinct, Targetable Signatures for Susceptibility and Severity. Genome Med (2020) 12(10):e213. doi:10.1186/s13073-020-00823-5
26. Burtis CAJ, Caldwell J, MacCoss L, Benoit S, Norman J, et al. Laboratory Testing and Interpretation in Clinical Medicine. 7th edition. 2019.
